Expanded Access to Glecaprevir/ Pibrentasvir

Sponsor
AbbVie
Study ID
NCT03123965
Status
Approved For Marketing

Conditions

  • Hepatitis C Virus Infection

Eligibility Criteria

Sex
All
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • glecaprevir — DRUG
    Glecaprevir will be administered orally.
  • pibrentasvir — DRUG
    Pibrentasvir will be administered orally.

Study Details

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to glecaprevir/ pibrentasvir prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Key Dates

Status verified
Jan 2020

Related Studies